#Israel #CollPlant #Rehovot #LightSolver #Biotechnologies

CollPlant Secures $3.7 Million in Private Placement

CollPlant Biotechnologies, a pioneering technology firm at the forefront of deep-tech photonic computing and biotechnology, recently revealed its definitive agreements for a private placement valued at approximately $3.7 million. This initiative involves the issuance and sale of a total of 989,301 ordinary shares, coupled with unregistered warrants that allow the purchase of up to 1,483,952 additional shares. The placement was conducted at a combined price of $3.74 per share. The predominant backing for this move comes from CollPlant's existing investors, underscoring their confidence in the company’s ambitious strategic vision.

The funds raised through this private placement are intended to facilitate the acceleration of research and development efforts in CollPlant's subsidiary, LightSolver. Specifically, the focus will be on advancing and scaling its innovative laser-based supercomputing architecture and the Laser Processing Unit (LPU™) technology. This development is critical, as it aims to solve some of the most challenging computational bottlenecks faced by various industries, including artificial intelligence, financial engineering, and high-performance computing.

The private placement is anticipated to close around October 14, 2026, pending the fulfillment of standard closing conditions. H.C. Wainwright & Co. and Rodman & Renshaw LLC have been appointed as the exclusive joint placement agents for this transaction. The preliminary proceeds from the placement, before the deduction of related expenses, are projected to be approximately $3.7 million. This reinforces CollPlant's commitment to enhancing its technological capabilities in photonic computing, which has vast potential applications across diverse sectors.

In response to this fundraising initiative, CollPlant's management expressed optimism about the role of LightSolver's innovations in transforming modern computing. The company remains dedicated not just to advancing deep-tech photonic computing but also to sustaining its leadership in regenerative medicine through its groundbreaking work with plant-derived recombinant human collagen technologies.

The anticipated technological advancements are expected to position CollPlant favorably in a competitive landscape, addressing significant challenges that arise from the increasing demand for powerful computational resources in numerous fields. Additionally, these advancements highlight the company's robust research framework and its capability to deliver pioneering solutions amidst rapid technological evolution.

CollPlant indicated that these securities are being offered under an exemption from the registration requirement as stipulated in the Securities Act of 1933. Consequently, the company will file a registration statement with the U.S. Securities and Exchange Commission to cover the resale of the shares generated through this private placement.

This fundraising effort not only aims at uplifting CollPlant’s current financial standing but also marks a significant step in the integration of cutting-edge technologies in their business model. The firm’s dedication to innovation in both laser-based computing and regenerative medicine posits it as a transformative player in the realm of biotechnology, ultimately driving progress in both sectors towards more efficient and advanced solutions for some of today's pressing challenges.

As CollPlant moves forward, the collaboration with investors and the technological advancements anticipated through this funding unveil a promising future for the company’s continued success and impact.

For more information on CollPlant Biotechnologies and their current initiatives, visit www.collplant.com.